ECVT Ecovyst Inc.
Chemicals & Allied Products · NYSE · SEC CIK 1708035 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY44.6%
TTM net income YoY133.6%
TTM EPS YoY134.4%
Revenue 3-yr CAGR11.5%
Net income 3-yr CAGR-18.4%
Margins
Gross margin19.7%
Operating margin8.5%
Net margin3.7%
FCF margin2.8%
EBITDA margin15.9%
Returns
ROE5.9%
ROA2.3%
ROIC (approx.)5.4%
Asset turnover0.62x
Leverage & solvency
Liabilities / assets57.2%
Debt / equity0.81x
Current ratio1.82x
Interest coverage3.73x
Cash quality & payout
Operating cash flow / net income3.28x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue9.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $723.51M | $598.29M |
| Cost of revenue | $565.43M | $434.91M |
| Gross profit | $158.09M | $163.38M |
| R&D expense | — | $6.81M |
| SG&A expense | $66.02M | $65.39M |
| Operating income | $64.89M | $85.13M |
| Interest expense | $34.20M | $36.49M |
| Pretax income | $25.79M | $45.20M |
| Income tax | $19.50M | -$299,000 |
| Net income | -$71.13M | -$6.65M |
| EBITDA | $132.69M | $145.00M |
| EPS (basic) | -0.62 | -0.06 |
| EPS (diluted) | -0.61 | -0.06 |
| Weighted avg. shares (diluted) | 115.96M | 117.45M |
| Balance sheet | ||
| Cash & equivalents | $197.19M | $131.39M |
| Receivables | $85.31M | $53.20M |
| Inventory | $26.80M | $17.97M |
| Current assets | $319.36M | $303.71M |
| PP&E, net | $481.16M | $458.68M |
| Goodwill | $326.74M | $326.59M |
| Intangibles | $59.29M | $67.70M |
| Total assets | $1.26B | $1.80B |
| Current liabilities | $120.81M | $115.13M |
| Short-term debt | $0 | $8.73M |
| Long-term debt | $392.58M | $852.10M |
| Total debt | $392.58M | $860.83M |
| Total liabilities | $657.54M | $1.10B |
| Shareholders' equity | $603.44M | $700.46M |
| Net debt | $195.39M | $729.44M |
| Shares outstanding | 111.81M | 116.53M |
| Cash flow statement | ||
| Operating cash flow | $140.31M | $149.89M |
| Capital expenditure | $70.41M | $55.59M |
| Free cash flow | $69.89M | $94.30M |
| Investing cash flow | $435.41M | -$73.45M |
| Financing cash flow | -$524.96M | -$17.84M |
| Depreciation & amortization | $67.81M | $59.86M |
| Stock-based compensation | $9.75M | $11.13M |
| Share buybacks | $46.95M | $5.01M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.